Published in J Neural Transm (Vienna) on September 07, 2007
Sildenafil treatment attenuates lung and kidney injury due to overproduction of oxidant activity in a rat model of sepsis: a biochemical and histopathological study. Clin Exp Immunol (2011) 0.87
Repeated antidepressant therapy increases cyclic GMP signaling in rat hippocampus. Neurosci Lett (2009) 0.84
cGMP Signaling, Phosphodiesterases and Major Depressive Disorder. Curr Neuropharmacol (2011) 0.81
Sildenafil, a phosphodiesterase type 5 inhibitor, enhances the antidepressant activity of amitriptyline but not desipramine, in the forced swim test in mice. J Neural Transm (Vienna) (2012) 0.80
Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants. Depress Res Treat (2013) 0.76
Antidepressant-like activity of sildenafil following acute and subchronic treatment in the forced swim test in mice: effects of restraint stress and monoamine depletion. Metab Brain Dis (2016) 0.76
Effect of sildenafil on the activity of some antidepressant drugs and electroconvulsive shock treatment in the forced swim test in mice. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
Nitric Oxide Synthase Inhibitors as Antidepressants. Pharmaceuticals (Basel) (2010) 0.75
Methylene blue and its analogues as antidepressant compounds. Metab Brain Dis (2017) 0.75
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol (1978) 4.76
Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci (2002) 4.02
Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature (1998) 3.46
Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry (2006) 2.68
Nitric oxide as modulator of neuronal function. Prog Neurobiol (2001) 2.41
Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry (2002) 2.02
A cholinergic-adrenergic hypothesis of mania and depression. Lancet (1972) 1.97
Neurologic, psychological, and aggressive disturbances with sildenafil. Ann Pharmacother (2002) 1.96
Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci (2003) 1.74
Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry (2003) 1.71
Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depth. Behav Brain Res (1996) 1.43
Postmortem distribution of sildenafil in histological material. J Anal Toxicol (2005) 1.38
Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience (2002) 1.23
Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci U S A (2006) 1.23
mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J Comp Neurol (2003) 1.17
Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol Biochem Behav (2005) 1.15
Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience (1998) 1.00
Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test. Eur J Pharmacol (1999) 0.97
Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats. Pharmacol Biochem Behav (2004) 0.97
Nucleus accumbens muscarinic receptors in the control of behavioral depression: antidepressant-like effects of local M1 antagonist in the Porsolt swim test. Neuroscience (2001) 0.93
Augmentation of the NO-cGMP cascade induces anxiogenic-like effect in mice. J Physiol Pharmacol (2003) 0.91
Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav Brain Res (2002) 0.91
Cholinergic mechanisms in depression. Brain Res (1986) 0.90
Evidence for the involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of memantine in mice. Behav Brain Res (2006) 0.89
Effect of sildenafil on anxiety in the plus-maze test in mice. Pol J Pharmacol (2004) 0.89
Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. Eur Neuropsychopharmacol (2004) 0.89
Anxiolytic and antidepressant properties of methylene blue in animal models. Pharmacol Res (1997) 0.88
Idazoxan and 8-OH-DPAT modify the behavioral effects induced by either NA, or 5-HT, or dual NA/5-HT reuptake inhibition in the rat forced swimming test. Neuropsychopharmacology (2001) 0.88
Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients. Neuropsychopharmacology (2006) 0.87
Influence of sildenafil on central dopamine-mediated behaviour in male rats. Life Sci (2002) 0.82
Efficacy of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in remission from depression. Int Clin Psychopharmacol (2004) 0.82
NMDA receptor involvement in imipramine withdrawal-associated effects on swim stress, GABA levels and NMDA receptor binding in rat hippocampus. Life Sci (2002) 0.82
Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res (2003) 0.81
No antidepressant effect of biperiden compared with placebo in depression: a double-blind 6-week clinical trial. Psychiatry Res (1995) 0.81
In the rat forced swimming test, NA-system mediated interactions may prevent the 5-HT properties of some subacute antidepressant treatments being expressed. Eur Neuropsychopharmacol (2002) 0.81
Dose-dependent down-regulation of beta-adrenergic receptors after chronic intravenous infusion of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry (1988) 0.80
In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs. Behav Brain Res (2002) 0.80
Effects of myo-inositol versus fluoxetine and imipramine pretreatments on serotonin 5HT2A and muscarinic acetylcholine receptors in human neuroblastoma cells. Metab Brain Dis (2004) 0.80
Localization and characterization of cGMP-immunoreactive structures in rat brain slices after NO-dependent and NO-independent stimulation of soluble guanylyl cyclase. Brain Res (2005) 0.80
Serum anticholinergic activity and behavior following atropine sulfate administration in the rat. Pharmacol Biochem Behav (1997) 0.79
Involvement of the NMDA receptor, NO-cyclic GMP and nuclear factor K-beta in an animal model of repeated trauma. Hum Psychopharmacol (2005) 0.79
Human brain receptor alterations in suicide victims. Pharmacol Biochem Behav (1982) 0.78
Cholinergic-NO-cGMP mediation of sildenafil-induced antinociception. Indian J Exp Biol (2004) 0.78
Variability of chronic antidepressant treatments on beta-adrenergic receptor sites. Prog Neuropsychopharmacol Biol Psychiatry (1985) 0.78
Muscarinic receptor sequestration in SH-SY5Y neuroblastoma cells is inhibited when clathrin distribution is perturbed. J Neurochem (1996) 0.78
Ontogeny of muscarinic cholinergic supersensitivity in the Flinders Sensitive Line rat. Pharmacol Biochem Behav (1999) 0.77
Increased hippocampal nitric oxide synthase activity and stress responsiveness after imipramine discontinuation: role of 5HT 2A/C-receptors. Metab Brain Dis (2006) 0.77
Evidence that lithium induces a glutamatergic: nitric oxide-mediated response in rat brain. Neurochem Res (1994) 0.77
The adrenergic-cholinergic imbalance hypothesis of depression: a review and a perspective. Rev Neurosci (1994) 0.77
Muscarinic receptor subtypes in human neuroblastoma cell lines SH-SY5Y and IMR-32 as determined by receptor binding, Ca++ mobilization and northern blotting. J Pharmacol Exp Ther (1992) 0.76
Lithium modulation of cortical cyclic nucleotides: evidence for the Yin-Yang hypothesis. Eur J Pharmacol (1990) 0.75
Phenoxybenzamine and benextramine, but not 4-diphenylacetoxy-N-[2-chloroethyl]piperidine hydrochloride, display irreversible noncompetitive antagonism at G protein-coupled receptors. J Pharmacol Exp Ther (2005) 0.75
Recent advances in drug action and therapeutics: relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology. Br J Clin Pharmacol (2004) 1.25
Phasic craving for carbohydrate observed with citalopram. Int Clin Psychopharmacol (1996) 0.94
Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine. Behav Pharmacol (2003) 0.89
Early life trauma decreases glucocorticoid receptors in rat dentate gyrus upon adult re-stress: reversal by escitalopram. Neuroscience (2005) 0.83
The effects of sub-chronic clozapine and haloperidol administration on isolation rearing induced changes in frontal cortical N-methyl-D-aspartate and D1 receptor binding in rats. Neuroscience (2010) 0.80
Single photon emission computed tomography (SPECT) in obsessive-compulsive disorder before and after treatment with inositol. Metab Brain Dis (2004) 0.80
Combined chronic treatment with citalopram and lithium does not modify the regional neurochemistry of nitric oxide in rat brain. J Physiol Pharmacol (2004) 0.80
Inositol in the treatment of trichotillomania and compulsive skin picking. J Clin Psychiatry (2001) 0.77
Two alternatives to traditional sick leave programs. Pers J (1983) 0.75
Early suppression of striatal cyclic GMP may predetermine the induction and severity of chronic haloperidol-induced vacous chewing movements. Metab Brain Dis (2000) 0.75
The right to work in safety. Occup Health (Lond) (1972) 0.75
Rewarding employees for not using sick leave. Pers Adm (1983) 0.75